Loading...
SYRS logo

Syros Pharmaceuticals, Inc.OTCPK:SYRS Rapporto sulle azioni

Cap. di mercato US$10.7k
Prezzo delle azioni
US$0.0004
Il mio valore equo
Non disponibile
1Y-98.7%
7D0%
1D
Valore del portafoglio
​
Vista

Syros Pharmaceuticals, Inc.

Report azionario OTCPK:SYRS

Capitalizzazione di mercato: US$10.7k

Syros Pharmaceuticals (SYRS) Panoramica del titolo

Syros Pharmaceuticals, Inc. è una società biofarmaceutica che si concentra sullo sviluppo di trattamenti per i tumori ematologici maligni. Maggiori dettagli

SYRS analisi fondamentale
Punteggio fiocco di neve
Valutazione0/6
Crescita futura0/6
Prestazioni passate0/6
Salute finanziaria0/6
Dividendi0/6

Analisi del rischio

Gli ultimi report finanziari risalgono a più di un anno fa

Non ha una capitalizzazione di mercato significativa ( $11K )

Prezzo delle azioni altamente volatile negli ultimi 3 mesi rispetto al mercato US


SYRS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di Syros Pharmaceuticals, Inc.

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Syros Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$0.0004
Massimo di 52 settimaneUS$0.04
Minimo di 52 settimaneUS$0.000001
Beta0
Variazione di 1 mese100.00%
Variazione a 3 mesi100.00%
Variazione di 1 anno-98.71%
Variazione a 3 anni-99.90%
Variazione a 5 anni-99.90%
Variazione dall'IPO-99.90%

Notizie e aggiornamenti recenti

Recent updates

Seeking Alpha • Jul 02

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

Summary Syros Pharmaceuticals focuses on developing therapies for myeloid cancers. The main pipeline candidate is tamibarotene, with positive signals in phase 2 trial and a key data readout coming in Q4 2024. Financially, SYRS has $112.2 million in assets, but faces a high cash burn rate and potential need for more financing. Read the full article on Seeking Alpha
Seeking Alpha • Jan 14

Syros Pharmaceuticals: Rising Despite Dilution, A Must Look

Summary Syros Pharmaceuticals is a cancer-focused biotech working on therapies for blood cancer, with a main drug in development. The company's main program is tamibarotene, targeting specific myeloid cancers with high RARA gene expression. Syros has encouraging data from a phase 2 trial and is currently conducting a phase 3 trial, but lack of asset diversification and high risk should be considered. Read the full article on Seeking Alpha
Seeking Alpha • Sep 20

Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders

Summary Syros Pharmaceuticals has recently acquired its peer Tyme Technologies. The sole purpose of the merger was to acquire TYME's cash balance. Concurrently with the merger, the largest shareholders put in an additional $130m into the company at over 30% premium to current prices. This strong vote of confidence from insiders makes SYRS very interesting, especially when shares are below insiders' entry price. SYRS share price has just declined by 17%, presenting an attractive entry point. SYRS now trades materially below net cash while being fully funded to bring development programs to fruition. The merger between Syros Pharmaceuticals (SYRS) and Tyme Technologies (TYME) was announced in the beginning of July and closed last Friday. This opportunity attracted our interest purely from the merger arb perspective but it actually had two angles to it (with the second one being the key point of this article): Pure merger arbitrage play - pretty much till the closing the spread on the merger stood at 20-40% (chart below) and we could not see any real risks in this transaction despite our best efforts to dig something out. Although such a wide spread on a merger with limited risks might seem too-good-to-true, we actually spot similar opportunities quite often in the less analyzed microcap space and cover them on our premium service Special Situation Investing. The merger arb aspect of the transaction has now fully played out, but there is another angle to the story. Another angle of TYME / SYRS transaction is that SYRS is a very well-positioned pharma company with an attractive development portfolio and this merger simply was an opportunity to acquire SYRS at 20-30% discount to the prevailing market prices by buying it through TYME. Now that the merger closed, one can no longer acquire TYME stock with hopes it will convert to SYRS, but luckily enough SYRS is now itself trading materially below the levels of the merger announcement, presenting an equally attractive opportunity as was acquiring it through TYME. Why the wide spread on the merger? Note: You can easily skip to the next section as this one only looks at a strange market inefficiency in these types of situations. TYME/SYRS Merger Spread Despite our attempts to find an explanation for this wide 20-40% spread, we could not find anything. So in the end we concluded that this is one of those micro-cap merger arbitrage situations where the market is simply not paying attention and our research actually gives us an edge. We love these types of opportunities and covered these regularly on Special Situation Investing. The spread on SYRS / TYME merger seemed completely overblown given the short expected closing timeline, persistently cheap SYRS hedging fees and very low risk of merger termination. The merger was basically an equity raise for SYRS. The buyer openly stated that it was interested solely in TYME's net cash position ($60m) to enhance its liquidity and indicated that TYME's existing drug development program will be put on hold. Shareholder approvals seemed guaranteed as around 35% of SYRS and 30% of TYME shares had already been in support. The PIPE financing for an additional $130m from the largest shareholders at a premium to the market prices added further confidence that every single party of the transaction wants this to close successfully. As expected, shareholder approvals were received on the 15th of September and the merger closed a day later. As further proof of market inefficiency in these types of situations, the spread still persisted even after the shareholder approval. After the vote SYRS issued an announcement stating that the merger will close the next day but the spread persisted and even increased slightly to 10%. Only by the end of the day the spread was finally eliminated. What's next for SYRS? Note: post-merger closing, SYRS has effected a 10-to-1 reverse stock split. Further calculations refer to SYRS's share price and count after the split. Aside from raising cash through the merger with TYME, SYRS also simultaneously did a huge $130m PIPE (vs $50m market cap at the time) at $0.94/share ($9.40/share adjusted for the recent split). The participants were mostly major shareholders of the company - large and reputable PE firms including Bain Capital, Invus Public Equities, Ally Bridge MedAlpha, and others. SYRS co-founder and founding investor Flagship Pioneering also participated. The fact that these firms, who have significantly more knowledge and information about the SYRS pipeline have put that much money at over 30% premium to current prices adds significant confidence in the value of the company's current pipeline. It's no secret that biopharma investing is largely a gamble. However, one thing for sure is that such reputable firms do not like throwing good money after the bad, and especially not in this size. Both transactions have now provided SYRS with enough cash runway through 2025. Post-merger, SYRS has 27.9m of outstanding shares and total cash of ~$240m (after deducting transaction expenses). Net cash is at ~$200m or ~$7.16 per SYRS share. SYRS is down 17% on the first day after the merger close and now sits close to an all-time-low at $6.08/share. The stock is currently trading 15% below net cash and over 35% discount to where the largest shareholders have just made a material investment. SYRS Net Cash Before the merger, SYRS used to trade at up to 8-10% discount to net cash. However, right now the company is in much better shape - a very strong cash position and no financing/dilution risk until 2026 - should be enough to advance its main treatment Tamibarotene into commercialization. If Tamibarotene shows good phase 3 results, the upside from current levels will be very material. These points, as well as the recent vote of confidence from major shareholders, suggest that 15% discount to net cash is overly punitive.
Seeking Alpha • Sep 13

Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609

Syros Pharmaceuticals (NASDAQ:SYRS) on Tuesday said the U.S. FDA had granted an orphan drug designation to its inhibitor SY-5609 for the treatment of pancreatic cancer. SY-5609 is currently being assessed in combination with chemotherapy for the treatment of patients with relapsed metastatic pancreatic cancer, SYRS said in a statement. The FDA's orphan drug designation program expedites the development and evaluation of a drug or biological product to prevent a rare disease or condition. SYRS stock +4.5% to $0.80 after hours.
Seeking Alpha • Aug 08

Syros Pharmaceuticals Q2 2022 Earnings Preview

Syros Pharmaceuticals (NASDAQ:SYRS) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.41 (-13.9% Y/Y) and the consensus Revenue Estimate is $4.78M (-7.4% Y/Y). Over the last 1 year, SYRS has beaten EPS estimates 50% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 3 upward revisions and 0 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

Rendimenti per gli azionisti

SYRSUS BiotechsUS Mercato
7D0%1.2%1.1%
1Y-98.7%34.6%28.7%

Ritorno vs Industria: SYRS ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 34.6 % nell'ultimo anno.

Rendimento vs Mercato: SYRS ha avuto una performance inferiore al mercato US che ha registrato un rendimento 28.7 % nell'ultimo anno.

Volatilità dei prezzi

Is SYRS's price volatile compared to industry and market?
SYRS volatility
SYRS Average Weekly Movement156.5%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di SYRS è stato volatile rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale di SYRS è diminuita da 843% a 157% nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
2011n/an/awww.syros.com

Syros Pharmaceuticals, Inc. è una società biofarmaceutica che si concentra sullo sviluppo di trattamenti per le neoplasie ematologiche. I principali prodotti candidati dell'azienda sono il tamibarotene, un agonista selettivo del recettore alfa dell'acido retinoico, in fase di sperimentazione clinica di Fase III per un sottogruppo genomicamente definito di pazienti affetti da sindrome mielodisplastica e di Fase II per pazienti affetti da leucemia mieloide acuta; SY-2101, una nuova forma orale di triossido di arsenico per il trattamento di pazienti affetti da leucemia promielocitica acuta; e SY-5609, un inibitore della chinasi 7 ciclina-dipendente, che è in fase I di sperimentazione clinica in pazienti con tumori solidi avanzati selezionati. L'azienda, precedentemente nota come LS22, Inc. ha cambiato nome in Syros Pharmaceuticals, Inc. nell'agosto 2012.

Syros Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Syros Pharmaceuticals con la sua capitalizzazione di mercato?
SYRS statistiche fondamentali
Capitalizzazione di mercatoUS$10.73k
Utili (TTM)-US$97.81m
Ricavi(TTM)US$386.00k
0.0x
Rapporto P/S
0.0x
Rapporto P/E

SYRS è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
SYRS Conto economico (TTM)
RicaviUS$386.00k
Costo del fatturatoUS$88.64m
Profitto lordo-US$88.25m
Altre speseUS$9.56m
Utili-US$97.81m

Ultimi utili riportati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)0
Margine lordo0.00%
Margine di profitto netto0.00%
Rapporto debito/patrimonio netto0.0%

Come si è comportato SYRS nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/24 10:43
Prezzo dell'azione a fine giornata2026/05/22 00:00
Utili2024/09/30
Utili annuali2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Syros Pharmaceuticals, Inc. è coperta da 4 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Mark BreidenbachOppenheimer & Co. Inc.
Zegbeh JallahRoth Capital Partners
Philip NadeauTD Cowen